Literature DB >> 21975742

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.

Laura Amato1, Silvia Minozzi, Marina Davoli, Simona Vecchi.   

Abstract

BACKGROUND: Maintenance treatments are effective in retaining patients in treatment and suppressing heroin use. Questions remain regarding the efficacy of additional psychosocial services.
OBJECTIVES: To evaluate the effectiveness of any psychosocial plus any agonist maintenance treatment versus standard agonist treatment for opiate dependence SEARCH STRATEGY: We searched the Cochrane Drugs and Alcohol Group trials register (June 2011), Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 6, 2011), PUBMED (1996 to 2011); EMBASE (January 1980 to 2011); CINAHL (January 2003 to 2011); PsycINFO (1985 to 2003) and reference list of articles. SELECTION CRITERIA: Randomised controlled trials and controlled clinical trial comparing any psychosocial plus any agonist with any agonist alone for opiate dependence. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality quality and extracted data. MAIN
RESULTS: 35 studies, 4319 participants, were included. These studies considered thirteen different psychosocial interventions. Comparing any psychosocial plus any maintenance pharmacological treatment to standard maintenance treatment, results do not show benefit for retention in treatment, 27 studies, 3124 participants, RR 1.03 (95% CI 0.98 to 1.07), abstinence by opiate during the treatment, 8 studies, 1002 participants, RR 1.12 (95% CI 0.92 to 1.37), compliance, three studies, MD 0.43 (95% CI -0.05 to 0.92), psychiatric symptoms, 3 studies, MD 0.02 (-0.28 to 0.31), depression, 3 studies, MD -1.70 (95% CI -3.91 to 0.51) and results at the end of follow up as number of participants still in treatment, 3 studies, 250 participants, RR 0.90 (95% CI 0.77 to 1.07) and participants abstinent by opioid, 3 studies, 181 participants, RR 1.15 (95% CI 0.98 to 1.36). Comparing the different psychosocial approaches, results are never statistically significant for all the comparisons and outcomes. AUTHORS'
CONCLUSIONS: For the considered outcomes, it seems that adding any psychosocial support to standard maintenance treatments do not add additional benefits. Data do not show differences also for contingency approaches, contrary to all expectations. Duration of the studies was too short to analyse relevant outcomes such as mortality. It should be noted that the control intervention used in the studies included in the review on maintenance treatments, is a program that routinely offers counselling sessions in addition to methadone; thus the review, actually, did not evaluate the question of whether any ancillary psychosocial intervention is needed when methadone maintenance is provided, but the narrower question of whether a specific more structured intervention provides any additional benefit to a standard psychosocial support. These interventions probably can be measured and evaluated by employing diverse criteria for evaluating treatment outcomes, aimed to rigorously assess changes in emotional, interpersonal, vocational and physical health areas of life functioning.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975742     DOI: 10.1002/14651858.CD004147.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  98 in total

1.  A randomized, controlled trial of the efficacy of an interoceptive exposure-based CBT for treatment-refractory outpatients with opioid dependence.

Authors:  Michael W Otto; Bridget A Hearon; R Kathryn McHugh; Amanda W Calkins; Elizabeth Pratt; Heather W Murray; Steven A Safren; Mark H Pollack
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.

Authors:  Phoebe A Cushman; Jane M Liebschutz; Bradley J Anderson; Merredith R Moreau; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2016-06-11

3.  An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain.

Authors:  Declan T Barry; Mark Beitel; Christopher J Cutter; David A Fiellin; Robert D Kerns; Brent A Moore; Lindsay Oberleitner; Lynn M Madden; Christopher Liong; Joel Ginn; Richard S Schottenfeld
Journal:  Drug Alcohol Depend       Date:  2018-11-13       Impact factor: 4.492

4.  Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study.

Authors:  Björn Philips; Peter Wennberg; Per Konradsson; Johan Franck
Journal:  Eur Addict Res       Date:  2018-01-19       Impact factor: 3.015

5.  Canada Is in Urgent Need to Expand Opioid Agonist Treatment.

Authors:  Eugenia Oviedo-Joekes
Journal:  Can J Psychiatry       Date:  2017-07       Impact factor: 4.356

6.  County-level access to opioid use disorder medications in medicare Part D (2010-2015).

Authors:  Amanda J Abraham; Grace Bagwell Adams; Ashley C Bradford; William D Bradford
Journal:  Health Serv Res       Date:  2019-01-21       Impact factor: 3.402

Review 7.  Supervised dosing with a long-acting opioid medication in the management of opioid dependence.

Authors:  Rosella Saulle; Simona Vecchi; Linda Gowing
Journal:  Cochrane Database Syst Rev       Date:  2017-04-27

8.  The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders.

Authors:  Elizabeth C Saunders; Mark P McGovern; Chantal Lambert-Harris; Andrea Meier; Bethany McLeman; Haiyi Xie
Journal:  Am J Addict       Date:  2015-09-21

9.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15

10.  Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.

Authors:  Andrea K Finlay; Ingrid A Binswanger; Christine Timko; David Smelson; Matthew A Stimmel; Mengfei Yu; Tom Bowe; Alex H S Harris
Journal:  J Subst Abuse Treat       Date:  2018-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.